Phase i study of S-trans, trans-farnesylthiosalicylic acid (Salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies

Talha Badar, Jorge E. Cortes, Farhad Ravandi, Susan O'Brien, Srdan Verstovsek, Guillermo Garcia-Manero, Hagop Kantarjian, Gautam Borthakur

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Fingerprint

Dive into the research topics of 'Phase i study of S-trans, trans-farnesylthiosalicylic acid (Salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences